There are currently 48 active clinical trials seeking participants for Solid Tumors research studies. The states with the highest number of trials for Solid Tumors participants are Texas, California, New York and Florida.
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Recruiting
This study is open to adults with different types of advanced cancer (solid tumors) that are accessible for injection and/or biopsy. This is a study for people with a life expectancy of at least 3 months after starting study treatment. The purpose of this study is to find the highest dose of a medicine called BI 1831169 that people with advanced cancer can tolerate when taken with or without a type of antibody called a checkpoint inhibitor (anti-PD-1 antibody). Another purpose is to check whethe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/22/2025
Locations: Banner MD Anderson Cancer Center-Gilbert-55251, Gilbert, Arizona +40 locations
Conditions: Solid Tumors
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Recruiting
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/22/2025
Locations: Southern Cancer Center, Daphne, Alabama +162 locations
Conditions: Solid Tumors
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Recruiting
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the par... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2025
Locations: Arizona Cancer Center at UMC North ( Site 0018), Tucson, Arizona +666 locations
Conditions: Solid Tumors, Hematologic Malignancies
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Recruiting
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: UCLA Healthcare Hematology-Oncology, Santa Monica, California +8 locations
Conditions: Solid Tumors, Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Recruiting
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Mayo Clinic Hospital, Phoenix, Arizona +31 locations
Conditions: Solid Tumors, Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC)
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Recruiting
A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California +12 locations
Conditions: Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration, FGFR3 Gene Mutation, Advanced Solid Tumors, FGFR4 Gene Mutation, FGFR4 Gene Fusions, FGF19 Gene Amplification, FGF19 Gene Overexpression, FGFR3 Gene Fusions, Locally Advanced Unresectable Hepatocellular Carcinoma
PanTheR Registry Trial
Recruiting
This study is a multicenter, observational, post-marketing, registry study designed to track the safety and performance of the RenovoCath® device and assess survival outcomes in patients diagnosed with solid tumors who are treated with localized intra-arterial (IA) delivery of therapeutic agents to solid tumors using the RenovoCath® catheter.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Baptist Health South Florida, Coral Gables, Florida +2 locations
Conditions: Solid Tumors
A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
Recruiting
This study will test the safety of a drug called PF-08046031 in participants with melanoma and other solid tumors that have no current approved treatment or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. The study will have 3 parts. Part A and B of the study will find out how much PF-08046031 should be given to participants. Part C will use the information from Parts A and B to see if... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate, Los Angeles, California +12 locations
Conditions: Malignant Melanoma, Melanoma, Metastatic Melanoma, Solid Tumors
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Recruiting
The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma and treated with myelosuppressive chemotherapy.
Gender:
ALL
Ages:
Between 1 month and 17 years
Trial Updated:
08/13/2025
Locations: New York Medical College, Valhalla, New York +3 locations
Conditions: Solid Tumors, Lymphoma
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Recruiting
The purpose of this clinical trial (called the FLOTILLA study) is to give continued access to the study medicines, as well as safety follow-up, for participants in prior clinical trials of encorafenib and/or binimetinib. All participants who took part in earlier encorafenib and/or binimetinib studies may participate the FLOTILLA study if they are still benefiting from the use of the study medicines. This will be determined by the study doctor. People may not participate in the FLOTILLA study if... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: St. Joseph's Hospital and Medical Center, Phoenix, Arizona +62 locations
Conditions: Solid Tumors
Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors
Recruiting
To study possible biomarkers that may be related to how SAR444881 works (either alone or when combined with cemiplimab) in participants with solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Md Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumors
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
Recruiting
Background: Blood, tissue, and tumor cells contain genes. Genes are made up of DNA. DNA is the instruction book for each cell. In some people with cancer, the genes that might have slowed the growth of their tumor were turned off. Researchers want to see if a new drug can turn the genes back on and slow the tumor growth. The drug is called Aza-TdC. Objective: To test the safety of Aza-TdC, and to find out the dose of this drug that can be safely given to humans. Eligibility: People ages 18... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Neoplasms, Solid Tumors